PYC Therapeutics (ASX:PYC) received all regulatory approvals to start human trials of its drug candidate for polycystic kidney disease, the company said in a Monday Australian bourse filing.
Polycystic kidney disease is a life-changing disease where multiple cysts form throughout a patient's kidney that increase in size over time.
Dosing of patients in the single ascending dose study is expected to be completed in about 12 months with a budgeted cost of AU$10 million, per the filing. The primary endpoint is treatment-emergent adverse events and treatment-emergent serious adverse events.
The initial human safety and efficacy data are anticipated within the year, the filing added.
Company shares were up nearly 3% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。